Cargando…

Patiromer in a Patient with Severe Hyperkalemia on Incremental Hemodialysis with 1 Session per Week: A Case Report and Literature Review

Hyperkalemia is common in patients with ESRD, undergoing hemodialysis (HD), and is associated with an increase in hospitalization and mortality. Residual kidney function in long-term dialysis patients is associated with lower morbidity and mortality in HD patients. Although the 2015 National Kidney...

Descripción completa

Detalles Bibliográficos
Autores principales:	De La Flor, José C., Deira, Javier, Marschall, Alexander, Valga, Francisco, Linares, Tania, Monzon, Tania, Albarracín, Cristina, Ruiz, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case and Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299388/ https://www.ncbi.nlm.nih.gov/pubmed/34327218 http://dx.doi.org/10.1159/000516595

Ejemplares similares

Efficacy and Safety of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist in Real-Life: A Case Series of Patients in Maintenance Incremental Hemodialysis
por: De la Flor, José C., et al.
Publicado: (2022)

Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients—A Report of 10 Cases
por: De La Flor, José C., et al.
Publicado: (2021)

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients
por: Kovesdy, Csaba P., et al.
Publicado: (2018)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
por: De La Flor, José C., et al.
Publicado: (2023)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
por: Weir, Matthew R., et al.
Publicado: (2017)

Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
por: Colbert, Gates, et al.
Publicado: (2022)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
por: Bushinsky, David A, et al.
Publicado: (2015)

Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan Bahadur, et al.
Publicado: (2021)

Impacto de la corrección temprana de la hiponatremia en el pronóstico de la infección del síndrome respiratorio agudo grave del coronavirus 2 (SARS-CoV-2)
por: de La Flor, José C., et al.
Publicado: (2022)

The impact of the correction of hyponatremia during hospital admission on the prognosis of SARS-CoV-2 infection()
por: de La Flor, José C., et al.
Publicado: (2022)

A curious case of persistently relapsing hyperkalemia in an ESRD patient on maintenance hemodialysis following bioprosthetic aortic valve replacement – a potential case for the use of the new agent, patiromer, for hyperkalemia management
por: Onuigbo, Macaulay Amechi Chukwukadibia, et al.
Publicado: (2016)

Pharmacodynamic effects of the K(+) binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats
por: Iyer, Sai Prasad N., et al.
Publicado: (2020)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review
por: Beccari, Mario V, et al.
Publicado: (2017)

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia
por: Li, Lingyun, et al.
Publicado: (2016)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
Publicado: (2019)

Reductions in systolic blood pressure achieved by hypertensives with three isometric training sessions per week are maintained with a single session per week
por: Cohen, Daniel D, et al.
Publicado: (2023)

Course of Hyperkalemia in Patients on Hemodialysis
por: Spinowitz, Bruce, et al.
Publicado: (2022)

IHDIP: a controlled randomized trial to assess the security and effectiveness of the incremental hemodialysis in incident patients
por: Deira, Javier, et al.
Publicado: (2019)

Effective Delivery of Vagus Nerve Stimulation Requires Many Stimulations Per Session and Many Sessions Per Week Over Many Weeks to Improve Recovery of Somatosensation
por: Ruiz, Andrea D., et al.
Publicado: (2023)

SARS-CoV-2 screening in chronic hemodialysis patients in a third-level hospital and its peripheral centers: ‘one hour less in the Canary Islands’()
por: Valga, Francisco, et al.
Publicado: (2021)

Incremental and Once- to Twice-Weekly Hemodialysis: From Experience to Evidence
por: Obi, Yoshitsugu, et al.
Publicado: (2017)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Expanded hemodialysis: what’s up, Doc?
por: García-Prieto, Ana, et al.
Publicado: (2023)

Role of extended hemodialysis in COVID-19: a case report()
por: Valga, Francisco, et al.
Publicado: (2020)

Case report: Patiromer-induced hypercalcemia
por: Wiederkehr, Michael R., et al.
Publicado: (2019)

Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin–Angiotensin–Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective
por: Fischer, Barbara, et al.
Publicado: (2022)

Hematochezia in a Patient with Renal Failure and Hyperkalemia
por: Meira, Tânia, et al.
Publicado: (2015)

Hyperkalemia in patients undergoing hemodialysis: Its pathophysiology and management
por: Shibata, Shigeru, et al.
Publicado: (2021)

A Rare Case of Patiromer Induced Hypercalcemia
por: Kanduri, Swetha Rani, et al.
Publicado: (2021)

Feasibility of Incremental 2-Times Weekly Hemodialysis in Incident Patients With Residual Kidney Function
por: Chin, Andrew I., et al.
Publicado: (2017)

Narrative Review of Incremental Hemodialysis
por: Murea, Mariana, et al.
Publicado: (2019)

Assessing the Number of Patients Receiving 1:1 Sessions and Their Frequency per Week
por: Golchinheydari, Sirous
Publicado: (2023)

Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe Hyperkalemia
por: Ford, Martin, et al.
Publicado: (2021)

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)

Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect
por: Bhattarai, Shreeyukta, et al.
Publicado: (2019)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bar23a2lkngihfbkcgo8ssljoo